Compare Standard Lithium Ltd (SLI) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Standard Lithium Ltd vs Tango Therapeutics Inc. — how do they compare? Standard Lithium Ltd trades at $1.41 (market cap $354.24M), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 10.6× Standard Lithium Ltd's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Standard Lithium Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Standard Lithium Ltd for 24 Days and Tango Therapeutics Inc. for 0 Days on average.
| SLI | TNGX | |
|---|---|---|
Market Cap | $354.24M | $3.75B |
Volume | 1,656,773 | 9,619,106 |
Sector | Basic Materials | Health |
52-Week High | $5.65 | $32.90 |
52-Week Low | $1.38 | $7.50 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $217.16M | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Standard Lithium (SLI) trades at $1.43, down 4.03% today, with a bearish technical signal despite bullish oscillators. The company shows negative profitability with ROE at -15.55% and no current revenue, but has made significant progress on its Arkansas lithium project with recent offtake agreements and government support. Analyst consensus remains strongly bullish with 100% buy ratings and a $3.83 price target, representing 168% upside potential from current levels.
The investment case hinges on successful execution of the South West Arkansas project, which could begin production in 2029. Key risks include negative cash flow from operations, high capital requirements, and project timeline delays. The stock offers speculative upside if the company can transition from development to production phase successfully.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Standard Lithium Ltd
Standard Lithium Ltd. is a company focused on the development of lithium projects in North America, with a primary focus on extracting lithium from brine resources. Their flagship projects aim to utilize proprietary, advanced direct lithium extraction (DLE) technologies to produce high-purity lithium compounds in an environmentally responsible manner. The company seeks to become a key domestic supplier to the growing electric vehicle and battery storage markets.
Read more on SLI →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
